Kiniksa Reports Q1 2026 Earnings with Strong Revenue Growth

Kiniksa (KNSA) reported first-quarter earnings for 2026 showing strong revenue growth driven by its ARCALYST product. The company raised full-year revenue guidance and highlighted progress in clinical trials, while also noting improvements in gross-to-net trends.

By Motley Fool Transcribing · Motley Fool · June 1, 2026, 18:32 UTC

Kiniksa Reports Q1 2026 Earnings with Strong Revenue Growth

Tickers: $KNSA $KPTI

Topics: clinical_trials pharmaceuticals prescriber_adoption revenue_growth

Read the full article at Motley Fool

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC